Low Hormone Levels Linked to Midlife Depression
Perimenopausal women with lower allopregnanolone showed more depressive symptoms in a small early study.
Updated on Nov. 3, 2026 in Alzheimer’s
Researchers reported that lower levels of the brain-active hormone allopregnanolone were associated with greater depressive symptoms in perimenopausal women. The observational study was shared at The Menopause Society 2026 Annual Meeting in San Diego in October and is relevant to women navigating mood changes during the menopause transition.
Why it matters
Depression during perimenopause is common but often overlooked, and this study points to a possible biological link between a neuroactive hormone and mood symptoms. The findings may help shape future research into targeted treatments and support the case for treating perimenopausal depression as its own condition.
This observational study followed 50 perimenopausal women with untreated mild depression through weekly mood assessments over 8 weeks, with hormone levels available for 40 participants. Allopregnanolone levels were lower during periods of greater depressive symptoms, and the inverse association held after adjusting for estradiol, progesterone, and vasomotor symptom frequency. The study does not establish cause and effect and its small sample limits how broadly the results apply.
The players
The Menopause Society
A professional medical society focused on women's health during midlife, including menopause care and research.
Mass General Brigham
A Boston-based academic health system whose researchers conducted the study and which is known for major clinical research programs.
Weill Cornell Medicine
A New York City medical school and research center that is active in women's health and psychiatry research.
The details
Allopregnanolone is a neuroactive steroid derived from progesterone that interacts with receptors in the brain involved in calming the nervous system. Researchers measured the hormone in each participant at her highest and lowest depression scores on the Montgomery-Åsberg Depression Rating Scale, which runs from 0 to 60. Levels were lower when depressive symptoms were worse, and the link persisted after accounting for estradiol, progesterone, and hot flash frequency. Researchers suggested that allopregnanolone and synthetic versions of it could be investigated as possible treatments for perimenopausal depression.
Timeline
October 2026: Study shared at The Menopause Society 2026 Annual Meeting in San Diego.
Health Landscape
Allopregnanolone-based treatment was first approved in the United States in 2019 for postpartum depression, establishing the hormone as a therapeutic target. This perimenopause study extends that research into a midlife window when depression rates rise but targeted treatment options remain limited.
If you are in perimenopause and notice new or worsening low mood, it is worth raising with your clinician rather than assuming it is just part of the transition. Depression screening during midlife is a reasonable topic to bring up at your next checkup.
The takeaway
Depression during the menopause transition is worth treating as its own concern rather than dismissing it as a normal part of aging. Ask your doctor about depression screening if your mood has changed during perimenopause, and keep a simple log of symptoms to share at appointments.
Further reading
For more on how hormones and brain health intersect across life stages, explore our Alzheimer’s coverage.
Source note: This article includes information reported by Medscape.
